Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)

被引：0
|
作者：
Simpkins, Fiona
Nasioudis, Dimitrios
Wethington, Stephanie L.
Martin, Lainie P.
Tanyi, Janos Laszlo
Latif, Nawar A.
Torigian, Drew A.
Omran, Dalia K.
Rodriguez, Diego
Smith, Simon
Dean, Emma
Domchek, Susan M.
Drapkin, Ronny
Shih, Ie-Ming
Brown, Eric J.
Hwang, Wei-Ting
Armstrong, Deborah Kay
Gaillard, Stephanie
Giuntoli, Robert Lawrence, II
Liu, Joyce F.
机构：
[1] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Univ Penn, Dept Radiol, Philadelphia, PA USA
[4] AstraZeneca, R&D Oncol, Royston, England
[5] AstraZeneca, R&D Oncol, Cambridge, England
[6] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD USA
[7] Univ Penn, Dept Canc Biol, Philadelphia, PA USA
[8] Univ Penn, Abramson Family Canc Res Inst, Perelman Sch Med, Philadelphia, PA USA
[9] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5510
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
    Yumei Zhou
    Junfen Xu
    World Journal of Surgical Oncology, 22 (1)
  • [42] Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer
    Matulonis, U.
    Richard, P.
    Campos, S.
    Bryan, J.
    Lee, J.
    Kendal, D.
    Krasner, C.
    Berlin, S.
    Roche, M.
    Duska, L.
    Pereira, L.
    Horowitz, N.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S23 - S24
  • [43] A phase I trial of lapatinib in combination with carboplatin in patients with platinum sensitive recurrent epithelial ovarian cancer
    Kimball, K. J.
    Numnum, T. M.
    Estes, J. M.
    Kirby, T. O.
    Barnes, M. N.
    Alvarez, R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer
    Benigno, B. B.
    Burrell, M. O.
    Daugherty, P.
    Hernandez, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial (vol 16, pg 87, 2015)
    Oza, A. M.
    Cibula, D.
    Benzaquen, A. O.
    LANCET ONCOLOGY, 2015, 16 (02): : E55 - E55
  • [46] THE REAL-WORLD EFFECT OF OLAPARIB IN BRCA-DEPENDENT PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER PATIENTS IN POLAND
    Blecharz, P.
    Madry, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A443 - A443
  • [47] Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial
    Liu, Jihong
    Yin, Rutie
    Wu, Lingying
    Zhu, Jianqing
    Lou, Ge
    Wu, Xiaohua
    Zhou, Qi
    Gao, Yunong
    Kong, Beihua
    Lu, Xin
    Wang, Jing
    Chen, Youguo
    Cheng, Ying
    Wang, Yueling
    Lu, Weiguo
    Li, Wei
    Ma, Xin
    Hsu, Kate
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 714 - 722
  • [48] Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.
    Oza, Amit M.
    Cibula, David
    Oaknin, Ana
    Poole, Christopher John
    Mathijssen, Ron H. J.
    Sonke, Gabe S.
    Colombo, Nicoletta
    Spacek, Jiri
    Vuylsteke, Peter
    Hirte, Hal W.
    Mahner, Sven
    Plante, Marie
    Schmalfeldt, Barbara
    Mackay, Helen
    Rowbottom, Jacqui
    Tchakov, Ilian
    Friedlander, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Phase I pharmacology study of carboplatin and weekly paclitaxel in platinum-sensitive ovarian cancer patients with recurrent disease
    Aghajanian, C
    Sabbatini, P
    Hensley, M
    Spriggs, D
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 42 - 42
  • [50] Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study
    Fagotti, A.
    Paris, B.
    Grimolizzi, F.
    Fanfani, F.
    Vizzielli, G.
    Naldini, A.
    Scambia, G.
    GYNECOLOGIC ONCOLOGY, 2009, 113 (03) : 335 - 340
12345